TransPharma Announces Successful Completion Of Phase 1a Clinical Trial Of ViaDerm-GLP1 Agonist Indicated For The Treatment Of Type II Diabetes
Links shared publicly online about this topic.
- 869total visits
TransPharma Announces Successful Completion Of Phase 1a Clinical Trial Of ViaDerm-GLP1 Agonist Indicated For The Treatment Of Type II Diabetes
TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology,
View full resource at medicalnewstoday.com
Tags: Diabetes, Type 2 Diabetes, Drug, Pharma, Clinical Trial
Most Recently Shared on September 16, 2010 at 4:00 pm By:
TransPharma Announces Successful Completion Of Phase 1a Clinical Trial Of ViaDerm-GLP1 Agonist Indicated For The Treat... http://mnt.to/3JQV
TransPharma Announces Successful Completion Of Phase 1a Clinical Trial Of ViaDerm-GLP1 Agonist Indicated For The Treatment Of Type II Diabetes | Diabetes | Type 2 Diabetes | Diabetes Mellitus | Keyvive.com
keyvive.com — “TransPharma Announces Successful Completion Of Phase 1a Clinical Trial Of ViaDerm-GLP1 Agonist Indicated For The Treatment Of Type II Diabetes | Diabetes | Type 2 Diabetes | Diabetes Mellitus | Keyvive.com” View full resource at keyvive.com
Most Recently Shared on September 16, 2010 at 7:30 pm By:
TransPharma Announces Successful Completion Of Phase 1a Clinical Trial Of ViaDerm-GLP1… http://goo.gl/fb/qCld0
Advertisement
